middle.news
OncoSil’s regulatory wins point to a bigger commercial test
2:59pm on Tuesday 27th of October, 2026 AEDT
•
Medical Devices
Read Story
OncoSil’s regulatory wins point to a bigger commercial test
2:59pm on Tuesday 27th of October, 2026 AEDT
Key Points
Revenue increased 44% to $1.68 million
Net loss narrowed to $10.86 million
Cash balance stood at $6.48 million after $13.46 million of gross equity funding
TRIPP-FFX met both co-primary endpoints, but was not designed for formal arm-to-arm comparison
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE